Alaunos Therapeutics
TCRT
133 hedge funds and large institutions have $228M invested in Alaunos Therapeutics in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
50% more capital inflows, than outflows
Capital inflows: $12.3M | Capital outflows: $8.18M
12% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 33
4% more funds holding
Funds holding: 128 → 133 (+5)
0.43% more ownership
Funds ownership: 40.33% → 40.76% (+0.43%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
36% less call options, than puts
Call options by funds: $3.19M | Put options by funds: $5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$3.47M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.42M |
| 3 |
Renaissance Technologies
New York
|
+$998K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$965K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$947K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.04M |
| 2 |
Parametric Portfolio Associates
Seattle,
Washington
|
-$625K |
| 3 |
Morgan Stanley
New York
|
-$587K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$385K |
| 5 |
Belpointe Asset Management
Reno,
Nevada
|
-$339K |
TCRT Hedge Fund Activity: Q1 2018 in Review
133 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2018, worth a combined $228M — down 3.9% from $237M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TCRT positions and 10 closed out — a net gain of 7 holders — while 37 added to existing stakes and 33 trimmed.
The largest buyer was State Street, adding an estimated $3.47M. The largest seller was Susquehanna International Group, cutting an estimated $3.04M.
- 133 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2018, up from 128 in Q4 2017.
- Funds reported $228M of Alaunos Therapeutics stock for Q1 2018, down 3.9% quarter-over-quarter.
- 17 funds opened new Alaunos Therapeutics positions in Q1 2018 and 10 closed out, a net change of +7 holders.
- The largest Alaunos Therapeutics buyer in Q1 2018 was State Street, an estimated $3.47M added.
- The largest Alaunos Therapeutics seller in Q1 2018 was Susquehanna International Group, an estimated $3.04M sold.
Based on aggregated 13F filings for Q1 2018.